Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 23471415)

1.

Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice.

Iversen F, Yang C, Dagnæs-Hansen F, Schaffert DH, Kjems J, Gao S.

Theranostics. 2013;3(3):201-9. doi: 10.7150/thno.5743. Epub 2013 Feb 25.

2.

In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.

Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A.

Toxicol Appl Pharmacol. 2009 Apr 1;236(1):97-108. doi: 10.1016/j.taap.2009.01.014. Epub 2009 Jan 29.

PMID:
19371615
3.

Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life.

Sato A, Choi SW, Hirai M, Yamayoshi A, Moriyama R, Yamano T, Takagi M, Kano A, Shimamoto A, Maruyama A.

J Control Release. 2007 Oct 8;122(3):209-16. Epub 2007 May 3.

PMID:
17583369
4.

Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging.

Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN, De Smedt SC, Béhé M, Kissel T.

J Control Release. 2009 Sep 1;138(2):148-59. doi: 10.1016/j.jconrel.2009.05.016. Epub 2009 May 19.

PMID:
19463870
5.

Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight.

Jung S, Lee SH, Mok H, Chung HJ, Park TG.

J Control Release. 2010 Jun 15;144(3):306-13. doi: 10.1016/j.jconrel.2010.03.002. Epub 2010 Mar 4.

PMID:
20206653
6.

Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA.

Kano A, Moriyama K, Yamano T, Nakamura I, Shimada N, Maruyama A.

J Control Release. 2011 Jan 5;149(1):2-7. doi: 10.1016/j.jconrel.2009.12.007. Epub 2009 Dec 21.

PMID:
20005270
7.

Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance.

Merkel OM, Beyerle A, Librizzi D, Pfestroff A, Behr TM, Sproat B, Barth PJ, Kissel T.

Mol Pharm. 2009 Jul-Aug;6(4):1246-60. doi: 10.1021/mp900107v.

PMID:
19606864
8.

Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.

Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS, Ting G.

Anticancer Res. 2009 Jun;29(6):2111-20.

9.

Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN.

Acc Chem Res. 2012 Jul 17;45(7):1163-71. doi: 10.1021/ar300048p. Epub 2012 May 8.

PMID:
22568781
10.

The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, Kjems J.

Mol Ther. 2009 Jul;17(7):1225-33. doi: 10.1038/mt.2009.91. Epub 2009 Apr 28.

11.
12.

Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.

Ho EA, Osooly M, Strutt D, Masin D, Yang Y, Yan H, Bally M.

J Pharm Sci. 2013 Jan;102(1):227-36. doi: 10.1002/jps.23351. Epub 2012 Nov 6.

PMID:
23132529
13.

In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier.

Naeye B, Deschout H, Caveliers V, Descamps B, Braeckmans K, Vanhove C, Demeester J, Lahoutte T, De Smedt SC, Raemdonck K.

Biomaterials. 2013 Mar;34(9):2350-8. doi: 10.1016/j.biomaterials.2012.11.058. Epub 2012 Dec 20.

PMID:
23261216
14.

Effect of polymer structure on micelles formed between siRNA and cationic block copolymer comprising thiols and amidines.

Christie RJ, Miyata K, Matsumoto Y, Nomoto T, Menasco D, Lai TC, Pennisi M, Osada K, Fukushima S, Nishiyama N, Yamasaki Y, Kataoka K.

Biomacromolecules. 2011 Sep 12;12(9):3174-85. doi: 10.1021/bm2006714. Epub 2011 Aug 24.

PMID:
21863796
15.

Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production.

Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H.

J Control Release. 2009 Aug 4;137(3):234-40. doi: 10.1016/j.jconrel.2009.04.006. Epub 2009 Apr 8.

PMID:
19361546
16.

PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice.

Merdan T, Kunath K, Petersen H, Bakowsky U, Voigt KH, Kopecek J, Kissel T.

Bioconjug Chem. 2005 Jul-Aug;16(4):785-92.

PMID:
16029019
17.

Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer.

Chen Y, Wang W, Lian G, Qian C, Wang L, Zeng L, Liao C, Liang B, Huang B, Huang K, Shuai X.

Int J Nanomedicine. 2012;7:359-68. doi: 10.2147/IJN.S24083. Epub 2012 Jan 31.

18.

PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.

Däpp S, García Garayoa E, Maes V, Brans L, Tourwé DA, Müller C, Schibli R.

Nucl Med Biol. 2011 Oct;38(7):997-1009. doi: 10.1016/j.nucmedbio.2011.02.014. Epub 2011 Apr 21.

PMID:
21982571
19.

Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.

Li C, Wang C, Yang H, Zhao X, Wei N, Cui J.

J Pharm Pharmacol. 2012 Mar;64(3):372-82. doi: 10.1111/j.2042-7158.2011.01422.x. Epub 2011 Dec 16.

PMID:
22309269
20.

Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide.

Lee SH, Kim SH, Park TG.

Biochem Biophys Res Commun. 2007 Jun 1;357(2):511-6. Epub 2007 Apr 9.

PMID:
17434451
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk